Published in Vaccine Weekly, July 24th, 2002
Many types of tumor cells express the p53 antigen, which can elicit a T-cell-mediated immune response. Sjoerd H. van der Burg and colleagues at the Leiden University Medical Center in the Netherlands performed a phase I/II escalation study to determine the effect of a p53 vaccine in patients with colorectal cancer.
The investigators inoculated 15 patients who had advanced colorectal cancer with a recombinant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly